Turkish pharmaceuticals company Birgi Mefar Group (BMG) has entered into a definitive acquisition agreement with ADQ, an Abu Dhabi- based investment and holding company.
BMG is one of Turkey’s leading producers of sterile injectable products, such as vials and pre-filled syringes for vaccines, and has operations in over 30 countries.
This acquisition comes as part of ADQ’s efforts to build a fully integrated healthcare and life sciences platform in the UAE. It will provide ADQ with exposure to a fast-growing market of injectables and high-value treatments, such as vaccines, as well as access to a wide customer network ranging from large multinationals to local and regional players.
Moreover, the acquisition will enable BMG to join ADQ’s Healthcare and Life Science portfolio that aims to enhance manufacturing, distribution and commercialization capabilities, including the provision of sterile health products and injectable solutions.
Norton Rose Fulbright advised the shareholders of Turkish pharmaceuticals company Birgi Mefar Group (BMG). The team was led by corporate partners Ayse Yüksel Mahfoud (pictured) and Claire O’Donnell (pictured), with additional input from partner Matt Foster in collaboration with Pekin Bayar Mizrahi, Norton Rose Fulbright’s affiliate in Turkey, on the transaction.